Clinical trials: Cancer Patient
Leukemia, Myeloid, Chronic
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients with Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
- Trial name
- NCT00538109
- Testing
- Glivec®/Gleevec®
- Volunteers
- 8 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Radiotherapy; Adverse Effect, Dermatitis or Eczema, Breast Neoplasms
Laser InGaAlP (660Nm) to Prevent Radiodermatitis in Breast Cancer Patients Submitted to Radiation Therapy
Breast neoplasm is the second most common type in the world. Radiation therapy is a key component in the treatment of breast cancer. Acute skin reaction is one of the most common side effects of radiation therapy.
- Trial name
- NCT02003599
- Testing
- Laser therapy
- Where
- Brazil
- Volunteers
- 52 people
- Sponsor
- Universidade do Vale do Sapucai
Breast Cancer
A Prospective Study on Effect of Systemic Adjuvant Therapy on Cognitive and Brain Function of Breast Cancer Patients
The purpose of the study is to examine cognitive and brain function in stage I-III breast cancer patients who have undergone adjuvant systemic therapy (chemotherapy or chemotherapy plus anti-hormonal therapy) in comparison to a…
- Trial name
- NCT02078531
- Where
- Singapore
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Neuroendocrine Tumors
Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy
An open-labelled, uncontrolled, single-center Phase I/IIa clinical study to evaluate the safety of repeated infusions of AdVince into the hepatic artery in patients with metastatic neuroendocrine tumors (NETs), and if possible…
- Trial name
- RADNET (NCT02749331)
- Testing
- AdVince
- Where
- Sweden
- Volunteers
- 35 people
- Sponsor
- Uppsala University
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or…
- Trial name
- NCT06271837
- Testing
- Trastuzumab deruxtecan, Bevacizumab
- Where
- 29 sites in China
- Volunteers
- 127 people
- Sponsor
- AstraZeneca
Head and Neck Cancer, Radiation Toxicity
Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer
RATIONALE: Moving a salivary gland out of the area that will undergo radiation therapy may protect the gland from side effects of radiation therapy and may prevent xerostomia (dry mouth).
- Conditions
- Head and Neck Cancer, Radiation Toxicity, Xerostomia
- Trial name
- NCT00068237
- Testing
- salivary gland transfer, Post-operative radiation therapy
- Where
- 12 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- Radiation Therapy Oncology Group
Cancer, Injury of Liver
Implementing Online Patient-Provider Communication Into Clinical Practice
This interdisciplinary, international collaboration study, including the the Norwegian Health Economy Administration (HELFO) will evaluate the effectiveness and real-world implementation of an online patient-provider…
- Conditions
- Cancer, Injury of Liver, Diabetes
- Trial name
- OPPC (NCT00971139)
- Testing
- Access to an OPPC service
- Where
- Norway
- Volunteers
- 199 people
- Sponsor
- Oslo University Hospital
Solid Tumors
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
This phase Ib trial studies the best dose and side effects of alpelisib and cisplatin in treating patients with human papillomavirus (HPV) positive solid tumor malignancies.
- Trial name
- NCT02620839
- Testing
- Alpelisib, Cisplatin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Pamela Munster
Myxoid Liposarcoma
Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall (LIPO-MYX Trial)
After a screening, which consists of pathology confirmation, physical examination, magnetic resonance imaging (MRI), body computed tomography (CT) scan, blood tests, and case analysis on Multidisciplinary Team (MDT) meeting…
- Trial name
- LIPOMYX (NCT03816475)
- Testing
- Hypofractionated radiotherapy
- Where
- Poland
- Volunteers
- 35 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Advanced Malignant Solid Tumor
PRL3-Zumab in Patients With Advanced Solid Tumors
This is a multicenter, Phase II, open-label, single-dose-level (6 mg/kg) study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumors.
- Trial name
- China Phase II (NCT07541001)
- Testing
- PRL3-ZUMAB
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Intra-IMMUSG Pte Ltd
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory).
- Conditions
- Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT05286801
- Testing
- Atezolizumab, Biospecimen Collection, Computed Tomography
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Hepatocellular Carcinoma
A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma
The goal of this investigator-initiated, a single-arm, open-label, pilot study is to investigate the safety, tolerability, and efficacy of CD-801 treatment in subjects with advanced hepatocellular carcinoma.
- Trial name
- NCT06092112
- Testing
- CD-801
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Shanghai Changzheng Hospital
Neoplasm Metastasis
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech /…
- Trial name
- NCT00781612
- Testing
- Docetaxel, Paclitaxel, Pertuzumab
- Where
- 179 sites in United States, Australia and 33 more
- Volunteers
- 378 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma, Plasmocytoma
Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks.
- Trial name
- NCT00988312
- Testing
- autologous idiotype-protein pulsed dendritic cells
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- University Hospital Carl Gustav Carus
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Non Small Cell Lung Cancer
Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.
This is a single arm, one center, phaseⅡ study evaluating efficacy and safety of erlotinib as neoadjuvent treatment in patients with EBUS confirmed stage ⅢA N2 NSCLC with activating EGFR mutation in exon 19 or 21.
- Trial name
- ML25444 (NCT01217619)
- Testing
- erlotinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Baohui Han
Non-small-cell Lung Cancer
E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to determined the maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 administered continually twice daily in combination with…
- Trial name
- NCT00832819
- Testing
- E7080, Paclitaxel, Carboplatin
- Where
- 3 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Eisai Co., Ltd.
Liver Cancer
Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot…
- Trial name
- NCT00589030
- Testing
- brachytherapy, yttrium Y 90 glass microspheres
- Where
- United States
- Sponsor
- City of Hope Medical Center
Carcinoma, Small Cell Lung
Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with atezolizumab in participants who have…
- Trial name
- Match (NCT04622228)
- Testing
- Atezolizumab, Cisplatin, Carboplatin
- Where
- 8 sites in China
- Volunteers
- 56 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Chronic Myeloid
Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
The aim of this study was to evaluate the real-world treatment patterns, healthcare resource use and costs among patients newly diagnosed with CML who were treated with tyrosine kinase inhibitors (TKIs) in first- and second-line…
- Trial name
- NCT07188428
- Where
- United States
- Volunteers
- 2,298 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.